Online inquiry

IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15405MR)

This product GTTS-WQ15405MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets HAVCR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_032782.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84868
UniProt ID Q8TDQ0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15405MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2411MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ15380MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ8923MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ35MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ3621MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ13442MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ3802MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ11262MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW